{
  "nctId": "NCT03819478",
  "briefTitle": "Utilizing Protein During Weight Loss to Impact Physical Function and Bone",
  "officialTitle": "Effect of Protein Supplementation During Weight Loss on Older Adult Bone Health",
  "protocolDocument": {
    "nctId": "NCT03819478",
    "filename": "Prot_002.pdf",
    "label": "Study Protocol",
    "date": "2022-08-02",
    "uploadDate": "2023-10-20T17:10",
    "size": 278821,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT03819478/document/Prot_002.pdf",
    "hasProtocol": true,
    "hasSap": false,
    "hasIcf": false
  },
  "phase": [
    "NA"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "RANDOMIZED",
  "interventionModel": "PARALLEL",
  "masking": "TRIPLE",
  "enrollmentInfo": {
    "enrollmentCount": 187,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2017-05-03",
    "completionDate": "2022-04-28",
    "primaryCompletionDate": "2022-04-28",
    "firstSubmitDate": "2019-01-18",
    "firstPostDate": "2019-01-28"
  },
  "eligibilityCriteria": {
    "criteria": "Subjects are recruited using inclusion and exclusion criteria of the parent trial (UPLIFT; NCT03074643).\n\nInclusion Criteria:\n\n* 65-85 years\n* BMI: 30-45 kg/m2 or BMI 27.0 - \\<30.0 AND at least one of the following risk factors:\n\n  1. elevated waist circumference (\\>35 inches in women, \\>40 inches in men)\n  2. diabetes,\n  3. hypertension,\n  4. dyslipidemia,\n  5. or other obesity-related comorbidities: clinically manifest coronary artery disease \\[e.g., history of myocardial infarction, angina pectoris, coronary artery surgery, coronary artery procedures (e.g., angioplasty) if not within the past year\\], other atherosclerotic disease \\[e.g., peripheral arterial disease, abdominal aortic aneurysm, symptomatic carotid artery disease if not within the past year\\], sleep apnea, or osteoarthritis of the knee or hip.\n* No regular resistance training and/or aerobic exercise (\\>20 mins/d) for past 6 months\n* SPPB ≥3 to ≤10\n* No contraindications for safe and optimal participation in exercise training\n* Approved for participation by Medical Director (Dr. Lyles)\n* Willing to provide informed consent\n* Agree to all study procedures and assessments\n* Willing to consume protein/CHO supplements for up to 18 months\n* Able to provide own transportation to study visits and intervention sessions\n\nExclusion Criteria:\n\n* Weight loss (≥5%) in past 6 months\n* Dependent on cane or walker\n* Cognitive impairment (Montreal Cognitive Assessment, MoCA score \\<22)\n* Severe arthritis, or other musculoskeletal disorder\n* Joint replacement or other orthopedic surgery in past year\n* Uncontrolled resting hypertension (\\>160/90 mmHg);\n* Uncontrolled diabetes (hemoglobin A1c, HbA1c ≥8.0%)\n* Current or recent past (within 1 year) severe symptomatic heart disease, uncontrolled angina, stroke, chronic respiratory disease requiring oxygen; uncontrolled endocrine/metabolic disease; neurological or hematological disease; cancer requiring treatment in past year, except non-melanoma skin cancers; liver or renal disease; or clinically evident edema\n* Unstable Severe Depression\n* Serious conduction disorder, uncontrolled arrhythmia, or new Q waves or ST-segment depressions (\\>3 mm at rest or ≥2 mm with exercise)\n* Abnormal kidney function (estimated glomerular rate \\<30 based on serum creatinine, age, gender, and race)\n* Anemia (Hb\\<13 g/dL in men; \\<12 g/dL in women)\n* Drug abuse or excessive alcohol use (\\>7 drinks/week women; \\>14 drinks/week men)\n* Use of any tobacco or nicotine products in the past year\n* Osteoporosis (T-score \\< -2.5 on hip or spine scan)\n* Regular use of growth/steroid hormones, sex steroids or corticosteroids\n* Osteoporosis medication\n* Protein supplements (and unwilling to stop using for duration of study)\n* Weight loss medications or procedures\n* Current participation in another intervention study",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "65 Years",
    "maximumAge": "85 Years",
    "stdAges": [
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "18-month Change From Baseline in Total Hip Trabecular Volumetric Bone Mineral Density Assessed by Computed Tomography (CT) in mg/cm^3",
        "description": "To determine the effects of a higher protein / lower CHO diet vs. lower protein / higher CHO diet on the 18-month change from baseline in total hip trabecular volumetric bone mineral density (vBMD). Total hip trabecular vBMD (in mg/cm\\^3) was measured from the baseline and 18-month quantitative CT scans using the Mindways Model 3 phantom to calibrate the vBMD measures. The 18-month change in total hip trabecular vBMD from baseline is reported for this outcome measure.",
        "timeFrame": "Change from Baseline to Month 18"
      }
    ],
    "secondary": [
      {
        "measure": "6-month Change From Baseline in Percentage of Adipose Tissue Within the Lumbar Spine Bone Marrow as Assessed by Dual-energy Computed Tomography Algorithm",
        "description": "Percentage of adipose tissue within the lumbar spine bone marrow as assessed by a dual-energy computed tomography (CT) algorithm to determine the effects of a higher protein / lower CHO diet vs. lower protein / higher CHO diet. Percentage of adipose tissue within the bone marrow was measured from the baseline and 6-month dual-energy CT scans using a Mindways Model 3 phantom for calibration. The 6-month change in percentage of adipose tissue within the lumbar spine bone marrow from baseline is reported for this outcome measure.",
        "timeFrame": "Change from Baseline to Month 6"
      },
      {
        "measure": "18-month Change From Baseline in Percentage of Adipose Tissue Within the Lumbar Spine Bone Marrow as Assessed by Dual-energy Computed Tomography Algorithm",
        "description": "Percentage of adipose tissue within the lumbar spine bone marrow as assessed by a dual-energy computed tomography (CT) algorithm to determine the effects of a higher protein / lower CHO diet vs. lower protein / higher CHO diet. Percentage of adipose tissue within the bone marrow was measured from the baseline and 18-month dual-energy CT scans using a Mindways Model 3 phantom for calibration. The 18-month change in percentage of adipose tissue within the lumbar spine bone marrow from baseline is reported for this outcome measure.",
        "timeFrame": "Change from Baseline to Month 18"
      },
      {
        "measure": "6-month Change From Baseline in Femoral Bone Strength in kN",
        "description": "Subject-specific finite element models were created from the baseline and 6-month CT scans and femoral bone strength was assessed from a simulated test of a sideways fall. Bone strength was measured as the peak section force extracted at the femoral neck to determine the effects of a higher protein / lower CHO diet vs. lower protein / higher CHO diet on the 6-month change from baseline in femoral bone strength.",
        "timeFrame": "Change from Baseline to Month 6"
      },
      {
        "measure": "18-month Change From Baseline in Femoral Bone Strength in kN",
        "description": "Subject-specific finite element models were created from the baseline and 18-month CT scans and femoral bone strength was assessed from a simulated test of a sideways fall. Bone strength was measured as the peak section force extracted at the femoral neck to determine the effects of a higher protein / lower CHO diet vs. lower protein / higher CHO diet on the 18-month change from baseline in femoral bone strength.",
        "timeFrame": "Change from Baseline to Month 18"
      },
      {
        "measure": "18-month Change From Baseline in Femoral Cortical Thickness Assessed by Computed Tomography (CT) in mm",
        "description": "Cortical thickness of the proximal femur was assessed by a computed tomography (CT) based algorithm to determine the effects of a higher protein / lower CHO diet vs. lower protein / higher CHO diet on the 18-month change from baseline in femoral cortical thickness. Cortical thickness was measured from the baseline and 18-month CT scans, and the 18-month change from baseline (in mm) is reported for this outcome measure.",
        "timeFrame": "Change from Baseline to Month 18"
      },
      {
        "measure": "6-month Change From Baseline in Femoral Cortical Thickness Assessed by Computed Tomography (CT) in mm",
        "description": "Cortical thickness of the proximal femur was assessed by a computed tomography (CT) based algorithm to determine the effects of a higher protein / lower CHO diet vs. lower protein / higher CHO diet on the 6-month change from baseline in femoral cortical thickness. Cortical thickness was measured from the baseline and 6-month CT scans, and the 6-month change from baseline (in mm) is reported for this outcome measure.",
        "timeFrame": "Change from Baseline to Month 6"
      },
      {
        "measure": "18-month Change From Baseline in Vertebral Volumetric Bone Mineral Density in the Lumbar Spine Assessed by Computed Tomography (CT) in mg/cm^3",
        "description": "To determine the effects of a higher protein / lower CHO diet vs. lower protein / higher CHO diet on the 18-month change from baseline in vertebral volumetric bone mineral density (vBMD) in the lumbar spine. Trabecular vBMD (in mg/cm\\^3) was measured from the baseline and 18-month quantitative CT scans using the Mindways Model 3 phantom to calibrate the vertebral vBMD measures. The 18-month change in vertebral vBMD in the lumbar spine from baseline is reported for this outcome measure.",
        "timeFrame": "Change from Baseline to Month 18"
      },
      {
        "measure": "6-month Change From Baseline in Vertebral Volumetric Bone Mineral Density in the Lumbar Spine Assessed by Computed Tomography (CT) in mg/cm^3",
        "description": "To determine the effects of a higher protein / lower CHO diet vs. lower protein / higher CHO diet on the 6-month change from baseline in vertebral volumetric bone mineral density (vBMD) in the lumbar spine. Trabecular vBMD (in mg/cm\\^3) was measured from the baseline and 6-month quantitative CT scans using the Mindways Model 3 phantom to calibrate the vertebral vBMD measures. The 6-month change in vertebral vBMD in the lumbar spine from baseline is reported for this outcome measure.",
        "timeFrame": "Change from Baseline to Month 6"
      },
      {
        "measure": "6-month Change From Baseline in Total Hip Trabecular Volumetric Bone Mineral Density Assessed by Computed Tomography (CT) in mg/cm^3",
        "description": "To determine the effects of a higher protein / lower CHO diet vs. lower protein / higher CHO diet on the 6-month change from baseline in total hip trabecular volumetric bone mineral density (vBMD). Total hip trabecular vBMD (in mg/cm\\^3) was measured from the baseline and 6-month quantitative CT scans using the Mindways Model 3 phantom to calibrate the vBMD measures. The 6-month change in total hip trabecular vBMD from baseline is reported for this outcome measure.",
        "timeFrame": "Change from Baseline to Month 6"
      }
    ],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 1,
      "secondaryCount": 9,
      "otherCount": 0,
      "totalCount": 10
    },
    "studyDesign": {
      "phases": [
        "NA"
      ],
      "isRandomized": true,
      "isMasked": true,
      "interventionModel": "PARALLEL"
    },
    "overallComplexityScore": 84,
    "complexityCategory": "Highly Complex"
  },
  "collectionDate": "2025-09-22T02:30:02.113Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}